Evolus Inc (EOLS) Stock Price, Quote & News

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 949 284 4555

Website: www.evolus.com

Address:

520 Newport Center Drive, Suite 1200, Newport Beach, United States

lknite Sep. 15 at 6:07 PM

$EOLS amazing

1 · Reply

lknite Sep. 15 at 2:44 PM

$EOLS looks like the market makers are pushing it down for a better entry before letting it fly

0 · Reply

NVDAMillionaire Sep. 11 at 11:26 AM

$EOLS Really good write-up that perfectly summarizes EOLS's present situation. So if you want to bring your EOLS knowledge up to date or just discover EOLS, this is required reading. https://beyondspx.com/quote/EOLS/analysis/evolus-cold-x-innovation-and-portfolio-powering-growth-amidst-aesthetic-headwinds-nasdaq-eols

1 · Reply

BioTuesdays Sep. 8 at 3:56 PM

$EOLS has announced the appointment of Tatjana Mitchell as chief financial officer (CFO), effective today. https://biotuesdays.com/2025/09/08/tatjana-mitchell-joins-evolus-as-cfo/

1 · Reply

lknite Sep. 2 at 4:36 PM

$EOLS

0 · Reply

lknite Aug. 29 at 10:26 PM

$EOLS I once heard, "trading stocks is supposed to feel easy". Buying EOLS as this price is exactly that. I know its not super dramatic, just doubling your moneybover a few weeks.

0 · Reply

lknite Aug. 29 at 10:23 PM

$EOLS up up up i need to get my daytradingbuyingpower back up

0 · Reply

lknite Aug. 28 at 11:42 PM

$EOLS let's go!!!

0 · Reply

OpenOutcrier Aug. 25 at 12:31 PM

$EOLS (+3.5% pre) Evolus reports positive trial results for Evolysse Sculpt dermal filler https://ooc.bz/l/75038

0 · Reply

TA_Kongen Aug. 25 at 12:09 PM

$EOLS Ahh this is botox lmfao wtf

1 · Reply

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 8:30 AM EDT - 7 days ago

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Aug 25, 2025, 8:00 AM EDT - 21 days ago

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Aug 20, 2025, 8:00 AM EDT - 26 days ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Aug 8, 2025, 4:05 PM EDT - 5 weeks ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 5, 2025, 7:15 PM EDT - 5 weeks ago

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 5 weeks ago

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:05 AM EDT - 6 weeks ago

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Jul 22, 2025, 8:05 AM EDT - 7 weeks ago

Evolus to Report Second Quarter Financial Results on August 5, 2025

Jul 21, 2025, 5:20 PM EDT - 2 months ago

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Jul 9, 2025, 8:00 AM EDT - 2 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Jun 10, 2025, 8:00 AM EDT - 3 months ago

Evolysse™ Recognized in 2025 Shape Skin Awards

May 27, 2025, 4:15 PM EDT - 3 months ago

Evolus Announces Departure of its Chief Financial Officer

May 22, 2025, 8:00 AM EDT - 4 months ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 7, 2025, 7:13 PM EDT - 4 months ago

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 4 months ago

Evolus Reports First Quarter 2025 Results

May 5, 2025, 4:05 PM EDT - 4 months ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Apr 23, 2025, 8:00 AM EDT - 5 months ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 16, 2025, 8:00 AM EDT - 5 months ago

Evolus Announces Commercial Launch of Evolysse™

Apr 15, 2025, 8:00 AM EDT - 5 months ago

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 4, 2025, 11:18 PM EST - 6 months ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:17 PM EST - 6 months ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:05 PM EST - 6 months ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Feb 27, 2025, 8:00 AM EST - 7 months ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 7 months ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 18, 2025, 8:00 AM EST - 7 months ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 13, 2025, 1:45 PM EST - 7 months ago

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:30 PM EST - 7 months ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Jan 21, 2025, 8:00 AM EST - 8 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Jan 14, 2025, 2:00 PM EST - 8 months ago

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Nov 6, 2024, 7:28 PM EST - 11 months ago

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 4:05 PM EST - 11 months ago

Evolus Reports Third Quarter 2024 Results

Nov 1, 2024, 8:00 AM EDT - 11 months ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Oct 31, 2024, 2:02 PM EDT - 11 months ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 29, 2024, 8:00 AM EDT - 11 months ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 23, 2024, 8:00 AM EDT - 11 months ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Jul 31, 2024, 10:22 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:09 PM EDT - 1 year ago

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Evolus to Hold Investor Day on September 12, 2024

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

May 22, 2024, 7:00 AM EDT - 1 year ago

Evolus: Chiseling Away At The Aesthetic Market

May 20, 2024, 8:30 AM EDT - 1 year ago

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

lknite Sep. 15 at 6:07 PM

$EOLS amazing

1 · Reply

lknite Sep. 15 at 2:44 PM

$EOLS looks like the market makers are pushing it down for a better entry before letting it fly

0 · Reply

NVDAMillionaire Sep. 11 at 11:26 AM

1 · Reply

BioTuesdays Sep. 8 at 3:56 PM

$EOLS has announced the appointment of Tatjana Mitchell as chief financial officer (CFO), effective today. https://biotuesdays.com/2025/09/08/tatjana-mitchell-joins-evolus-as-cfo/

1 · Reply

lknite Sep. 2 at 4:36 PM

$EOLS

0 · Reply

lknite Aug. 29 at 10:26 PM

$EOLS I once heard, "trading stocks is supposed to feel easy". Buying EOLS as this price is exactly that. I know its not super dramatic, just doubling your moneybover a few weeks.

0 · Reply

lknite Aug. 29 at 10:23 PM

$EOLS up up up i need to get my daytradingbuyingpower back up

0 · Reply

lknite Aug. 28 at 11:42 PM

$EOLS let's go!!!

0 · Reply

OpenOutcrier Aug. 25 at 12:31 PM

$EOLS (+3.5% pre) Evolus reports positive trial results for Evolysse Sculpt dermal filler https://ooc.bz/l/75038

0 · Reply

TA_Kongen Aug. 25 at 12:09 PM

$EOLS Ahh this is botox lmfao wtf

1 · Reply

TA_Kongen Aug. 25 at 12:05 PM

$EOLS ??? Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp Looks good, no reaction.

0 · Reply

DCRMIA Aug. 21 at 9:40 AM

$EOLS "Mizuho Reiterates Outperform Rating on Evolus" https://www.investing.com/news/pro/mizuho-maintains-evolus-at-outperform-with-a-price-target-of-1900-4203836

1 · Reply

Damian23 Aug. 20 at 4:56 PM

$EOLS Q2 2025 revenue: $69.4 million; 2025 guidance: $295–$305 million. Current market cap: $461 million (updated). Debt: $154.5 million; Cash: $61.7 million. Shares outstanding: 64 million. Enterprise Value (EV) = Market Cap + Debt - Cash = 461M + 154.5M - 61.7M = $553.8 million. EV / 2025 revenue midpoint ($300M) = 553.8M / 300M = ~1.85x. Assume conservative 20% annual revenue growth after 2025. Projected revenue 2026 = $295M × 1.2 = $354 million. Projected revenue 2027 = $354M × 1.2 = $425 million. Using EV/Revenue multiple of 1.85x for 2027 (conservative): EV 2027 = $425M × 1.85 = $786 million. Equity value 2027 = EV - Debt + Cash = 786M - 154.5M + 61.7M = $693 million. Fair value per share = $693M / 64M = $10.8 per share. Current price ~$7.20 (based on market cap and shares) vs. fair value $10.8. Upside potential under conservative assumptions is about 50%.

0 · Reply

prismmarketview Aug. 20 at 2:18 PM

(NASDAQ: $EOLS) @Evolus has submitted its PMA application to the FDA for Evolysse™ Sculpt, its flagship injectable HA gel targeting mid-face volume restoration. Backed by strong pivotal trial data, Sculpt leverages innovative Cold-X™ technology and is expected to enter the highest-value dermal filler segment, with FDA approval anticipated in 2H 2026. This milestone expands Evolus’ portfolio and positions the company for continued growth in aesthetics. https://prismmarketview.com/evolus-submits-fda-premarket-approval-application-for-evolysse-sculpt-injectable-ha-gel/

0 · Reply

Allf2 Aug. 20 at 11:29 AM

$EOLS It's still cheap

0 · Reply

adaptnow Aug. 17 at 10:05 PM

$EOLS @Bilbo9494 could you please explain your reasoning as to why Club Evolus was a bad idea? Perhaps it would be perceived as a win for Evolus, but a loss for the practice? It would certainly be a win for the consumer. Evolus’ primary customer is the aesthetics practice, so if it was perceived as a loss for the practice, the whole strategy becomes a non-starter. Their primary customer decides not to promote Club Evolus. On the other hand, having a patient come back every 3 months means an appointment (aka opportunity to sell additional services), but if there is no willingness to spend more than the minimum Jeuveau treatment, it’s a loss leader that doesn’t translate into upside. If Evolus had a subscription base it might even out some of the lumpiness in cyclical quarterly sales revenue. So from that perspective, I understand their motivation to pursue this path.

1 · Reply

lknite Aug. 14 at 11:47 PM

$EOLS i like that 6.67, noice

0 · Reply

Estimize Aug. 13 at 8:00 PM

Wall St is expecting -0.15 EPS for $EOLS Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/eols?chart=historical&metric_name=eps&utm_c

0 · Reply

Allf2 Aug. 13 at 2:17 PM

$EOLS It's a little loaded

0 · Reply

lknite Aug. 13 at 2:40 AM

$EOLS i'll sell you my shares for 11.95, see ya after awhile

0 · Reply

lknite Aug. 13 at 12:47 AM

$EOLS yay!

0 · Reply

Premier24 Aug. 12 at 7:11 PM

$EOLS why the move?

0 · Reply

Market Cap	465.09M
Revenue (ttm)	266.27M
Net Income (ttm)	-50.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.94%
Debt to Equity Ratio	-7.80

Volume	1,540,700
Avg Vol	1,440,846
Day's Range	N/A - N/A
Shares Out	64.69M
Stochastic %K	3%
Beta	1.07
Analysts	Strong Sell
Price Target	$19.40